Sandoz delivered 9% revenue growth (7% in constant currency) for its second quarter. Adjusted earnings per share for the first half rose 17%. Shares traded up 7% on Aug. 5.
With autonomy from its former parent, Sandoz should be able to freely allocate resources to fit its best needs and grow the business.
Off-patent drugs face low- to mid-single-digit price erosion year over year, and regulatory actions and competition in the drug supply chain could increase headwinds.
|
Metric
|
SDZ
|
RDY
|
TEVA
|
|---|---|---|---|
Price/Earnings (Normalized) | 40.68 | 29.52 | 15.44 |
Price/Book Value | 4.12 | 2.53 | 5.31 |
Price/Sales | 3.27 | 2.79 | 2.38 |
Price/Cash Flow | 33.65 | 17.82 | 13.67 |
|
Metric
|
SDZ
|
RDY
|
TEVA
|
|---|---|---|---|
Quick Ratio | 0.50 | 1.31 | 0.46 |
Current Ratio | 1.05 | 1.90 | 0.88 |
Interest Coverage | 4.66 | 10.27 | 1.79 |
|
Metric
|
SDZ
|
RDY
|
TEVA
|
|---|---|---|---|
Return on Assets (Normalized) | — | 7.17% | 6.68% |
Return on Equity (Normalized) | — | 10.86% | 35.32% |
Return on Invested Capital (Normalized) | — | 9.39% | 14.43% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|FftQ^>l | LOCK|JgK# | $72B | |||
| Haleon PLC ADR
HLN
| LOCK|T!^qn@^ | LOCK|jS$ | $44B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|t^&nT@Y | LOCK|wj&G@ | $41B | |||
| Zoetis Inc Class A
ZTS
| LOCK|Y>glq@g | LOCK|j< | $30B | |||
| Viatris Inc
VTRS
| LOCK|wCgDLd | LOCK|th@ | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|W$x | LOCK|T# | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|RQ#^LB | LOCK|PSN | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|b&@YJ# | LOCK|HqQ | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|?G@!HL# | LOCK|RpZ& | $3B | |||
| Perrigo Co PLC
PRGO
| LOCK|#?pYK! | LOCK|y#@ | $2B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/b76d1412-e5af-4b94-8222-8cb66fe23dbe.jpg)
United States